Naho Yaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naho Yaguchi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Emi Sato
Department of Nursing University of Tokyo Health Science Tama Japan
1 shared publication- Haruka Okabe
Faculty of Nursing Tokai University School of Medicine Isehara Japan
1 shared publication Koichi Shiraishi
Department of Gastroenterology and Hepatology Tokai University School of Medicine Isehara Japan
1 shared publication- Kota Tsuruya
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
1 shared publication - Masako Shomura
Faculty of Nursing Tokai University School of Medicine Isehara Japan
1 shared publication Maya Sakakibara
Faculty of Nursing Tokai University School of Medicine Isehara Japan
1 shared publication
Latest Publications
- Open Access
- 30 November 2024
- Published by Wiley in Hepatology Research
- Vol. 55 (4) , 547-555
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan
Aim: This study aimed to comprehensively assess the incidence of immune‐related adverse events (irAEs) and the detection systems in place for patients with liver cancer undergoing treatment with immune checkpoint inhibitors (ICIs), using a self‐administered anonymous questionnaire. The questionnaire was designed to gather crucial insights into the management of irAEs in these patients.Methods: A self‐administered anonymous questionnaire was sent to 456 liver disease collaborative base hospitals and cancer care coordination base hospitals in Japan.Results: Responses were received from 112 facilities, indicating a response rate of 25%. The region with the highest response rate was Kanto (22%, 24 sites), followed by Kyushu (19%, 21 sites), Chubu (14%, 15 sites), and Kinki (14%, 15 sites). The number of patients with hepatocellular carcinoma (HCC) who received ICI treatment varied, with a mean ± SD of 20.4 ± 19.4 cases per year per facility. The number of full‐time physicians who provided ICI treatment for HCC was 4.2 ± 3.3 (mean ± SD), ranging from 0 to 24 per facility. Of these, the majority included hepatologists and oncologists, whose numbers were 3.3 ± 2.4 (mean ± SD) (range, 0–11) and 0.8 ± 1.0 (0–3), respectively. Gastroenterologists and internal medicine specialists participated in the treatment at some facilities.Conclusions: The survey results revealed that physicians administered ICI therapy for an average of 20 HCC cases per institution, with more than 17 types of irAEs reported. The most common irAEs were hepatic dysfunction, followed by thyroid dysfunction, skin disorders, interstitial pneumonia, and renal dysfunction.
- 30 November 2024
- Published by Wiley in Hepatology Research
- Vol. 55 (4) , 547-555
Open AccessImmune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan
Aim: This study aimed to comprehensively assess the incidence of immune‐related adverse events (irAEs) and the detection systems in place for patients with liver cancer undergoing treatment with immune checkpoint inhibitors (ICIs), using a self‐administered anonymous questionnaire. The questionnaire was designed to gather crucial insights into the management of irAEs in these patients.Methods: A self‐administered anonymous questionnaire was sent to 456 liver disease collaborative base hospitals and cancer care coordination base hospitals in Japan.Results: Responses were received from 112 facilities, indicating a response rate of 25%. The region with the highest response rate was Kanto (22%, 24 sites), followed by Kyushu (19%, 21 sites), Chubu (14%, 15 sites), and Kinki (14%, 15 sites). The number of patients with hepatocellular carcinoma (HCC) who received ICI treatment varied, with a mean ± SD of 20.4 ± 19.4 cases per year per facility. The number of full‐time physicians who provided ICI treatment for HCC was 4.2 ± 3.3 (mean ± SD), ranging from 0 to 24 per facility. Of these, the majority included hepatologists and oncologists, whose numbers were 3.3 ± 2.4 (mean ± SD) (range, 0–11) and 0.8 ± 1.0 (0–3), respectively. Gastroenterologists and internal medicine specialists participated in the treatment at some facilities.Conclusions: The survey results revealed that physicians administered ICI therapy for an average of 20 HCC cases per institution, with more than 17 types of irAEs reported. The most common irAEs were hepatic dysfunction, followed by thyroid dysfunction, skin disorders, interstitial pneumonia, and renal dysfunction.